| 1 | presence | 22,771 |
| 2 | absence | 9,285 |
| 3 | existence | 1,512 |
| 4 | metaregister | 255 |
| 5 | presence/absence | 109 |
| 6 | perpetuation | 47 |
| 7 | advisability | 20 |
| 8 | pervasiveness | 19 |
| 9 | abolishment | 15 |
| 10 | conclusiveness | 15 |
| 11 | absence/presence | 11 |
| 12 | orchestration | 10 |
| 13 | photophysics | 10 |
| 14 | supremacy | 10 |
| 15 | adaptiveness | 8 |
| 16 | 4'-position | 7 |
| 17 | enormity | 7 |
| 18 | sultanate | 7 |
| 19 | non-occurrence | 6 |
| 20 | principality | 6 |
| 21 | 'proportion | 5 |
| 22 | cocirculation | 5 |
| 23 | nonreceipt | 5 |
| 24 | patho-physiology | 5 |
| 25 | pathoetiology | 5 |
| 26 | presences | 5 |
| 27 | earliness | 4 |
| 28 | newness | 4 |
| 29 | over-expressions | 4 |
| 30 | rv-5h-egfp | 4 |
| 31 | transactivity | 4 |
| 32 | 3-alkenylation | 3 |
| 33 | 3-alkylation | 3 |
| 34 | explicitness | 3 |
| 35 | fracture/operation | 3 |
| 36 | full-texts | 3 |
| 37 | ionicity | 3 |
| 38 | multifunctionality | 3 |
| 39 | nonexistence | 3 |
| 40 | re-appearance | 3 |
| 41 | regimentation | 3 |
| 42 | sugammadex-rocuronium | 3 |
| 43 | up-take | 3 |
| 44 | 'characteristics | 2 |
| 45 | arg-vx001 | 2 |
| 46 | arm-forearm | 2 |
| 47 | avirulence | 2 |
| 48 | beef-consumption | 2 |
| 49 | cav- | 2 |
| 50 | cis-regulation | 2 |
| 51 | curer | 2 |
| 52 | curve-ness | 2 |
| 53 | disunity | 2 |
| 54 | dose/type | 2 |
| 55 | ecws | 2 |
| 56 | efficicacy | 2 |
| 57 | ethylacetate-fraction | 2 |
| 58 | extrudability | 2 |
| 59 | freguency | 2 |
| 60 | greying | 2 |
| 61 | hydrophosphination | 2 |
| 62 | imperfectness | 2 |
| 63 | inhibition/depletion | 2 |
| 64 | instalment | 2 |
| 65 | load-dependence | 2 |
| 66 | next-of-kin | 2 |
| 67 | non-adenomatous | 2 |
| 68 | non-eruption | 2 |
| 69 | non-presence | 2 |
| 70 | ocurrence | 2 |
| 71 | permissibility | 2 |
| 72 | pervasion | 2 |
| 73 | quick-disabilities | 2 |
| 74 | reinstallation | 2 |
| 75 | revitalisation | 2 |
| 76 | rls-quality | 2 |
| 77 | score/duration | 2 |
| 78 | shade-drying | 2 |
| 79 | theorisation | 2 |
| 80 | thrombovasculitis | 2 |
| 81 | timecourse | 2 |
| 82 | type-conformity | 2 |
| 83 | underweighting | 2 |
| 84 | 'region | 1 |
| 85 | 'toxemia | 1 |
| 86 | 0-6-month | 1 |
| 87 | 0.1mg/g | 1 |
| 88 | 0.450mg | 1 |
| 89 | 16g/day | 1 |
| 90 | 2,6-dideoxyhexoses | 1 |
| 91 | 23-o-methylation | 1 |
| 92 | 3'-amp-induced | 1 |
| 93 | 3-o-acetylation | 1 |
| 94 | 3.2g | 1 |
| 95 | 5-methoxy-moieties | 1 |
| 96 | 54mg | 1 |
| 97 | 5drop/kg | 1 |
| 98 | 8,9-positions | 1 |
| 99 | =2/5 | 1 |
| 100 | acute-exacerbations | 1 |
| 101 | adolescent-report | 1 |
| 102 | aleviations | 1 |
| 103 | anatomical/physiological | 1 |
| 104 | andinjustice | 1 |
| 105 | antennal- | 1 |
| 106 | anti-conservatism | 1 |
| 107 | axilla-surgery | 1 |
| 108 | banishment | 1 |
| 109 | bprs-score | 1 |
| 110 | brief-symptom-inventory-18 | 1 |
| 111 | broadbeam | 1 |
| 112 | bypass/resection | 1 |
| 113 | c1-carboxyl | 1 |
| 114 | ca2+-permeability | 1 |
| 115 | cattaneo-vernotte | 1 |
| 116 | cdc28 | 1 |
| 117 | cdh1-347g/ga | 1 |
| 118 | clarithromycin-amoxicillin | 1 |
| 119 | classical- | 1 |
| 120 | clinical-course | 1 |
| 121 | co-inhibitors | 1 |
| 122 | conut® | 1 |
| 123 | county- | 1 |
| 124 | cu-se | 1 |
| 125 | culture-negatives | 1 |
| 126 | cytodestruction | 1 |
| 127 | dam-to-placenta | 1 |
| 128 | decompression/release | 1 |
| 129 | deimplementation | 1 |
| 130 | dendrimerization | 1 |
| 131 | di-sulfate | 1 |
| 132 | didactic-only | 1 |
| 133 | disbeliefs | 1 |
| 134 | disease-spectrum | 1 |
| 135 | disproof | 1 |
| 136 | dw-r. | 1 |
| 137 | eclabion | 1 |
| 138 | endodrainage | 1 |
| 139 | entranceability | 1 |
| 140 | eortc-qlqc30 | 1 |
| 141 | erk- | 1 |
| 142 | eurotiales | 1 |
| 143 | f-60 | 1 |
| 144 | face/forehead | 1 |
| 145 | gastrin- | 1 |
| 146 | globality | 1 |
| 147 | gut-hepatic | 1 |
| 148 | hemorrhea | 1 |
| 149 | ho/co | 1 |
| 150 | hypermethylations | 1 |
| 151 | hypopnoea/hour | 1 |
| 152 | initial-pat | 1 |
| 153 | intermediating | 1 |
| 154 | jeju-do | 1 |
| 155 | keratitis/keratopathy | 1 |
| 156 | ldlr-cc | 1 |
| 157 | levels/patterns | 1 |
| 158 | liberal- | 1 |
| 159 | liquidform | 1 |
| 160 | lodogen | 1 |
| 161 | m-methoxyphenyl | 1 |
| 162 | maxillary- | 1 |
| 163 | menbunong | 1 |
| 164 | mensapo | 1 |
| 165 | mid-wbc | 1 |
| 166 | midazolam-group | 1 |
| 167 | midvault | 1 |
| 168 | minutia | 1 |
| 169 | mono-beta-xyloside | 1 |
| 170 | mono-ubiquitylation | 1 |
| 171 | msus- | 1 |
| 172 | myth-reality | 1 |
| 173 | n109 | 1 |
| 174 | naguales | 1 |
| 175 | near-clearing | 1 |
| 176 | nerve-nerve | 1 |
| 177 | nhe6 | 1 |
| 178 | nickel-producing | 1 |
| 179 | non-collection | 1 |
| 180 | non-consumption | 1 |
| 181 | nonactivation | 1 |
| 182 | nonpractice | 1 |
| 183 | nonrespect | 1 |
| 184 | o-iodoanilides | 1 |
| 185 | off-warfarin | 1 |
| 186 | over-ordination | 1 |
| 187 | over-recording | 1 |
| 188 | overgrading | 1 |
| 189 | overthinning | 1 |
| 190 | persistence/calcification | 1 |
| 191 | petichiae | 1 |
| 192 | post-clamping | 1 |
| 193 | pou5f1- | 1 |
| 194 | preemption | 1 |
| 195 | psc833- | 1 |
| 196 | pseudo-delayedness | 1 |
| 197 | purveyor | 1 |
| 198 | raloxifene- | 1 |
| 199 | reconsolidate | 1 |
| 200 | relationship-causation | 1 |
| 201 | remifentinal | 1 |
| 202 | restaging/follow-up | 1 |
| 203 | retro-claisen/retro-hetero-diels-alder | 1 |
| 204 | rhizomorphs | 1 |
| 205 | ring-cladding | 1 |
| 206 | ringer's-pretreated | 1 |
| 207 | s-oxygenations | 1 |
| 208 | selective-invasive | 1 |
| 209 | selenoamides | 1 |
| 210 | selenomethionine/kg | 1 |
| 211 | sham-tms | 1 |
| 212 | single-cpg | 1 |
| 213 | sirna-knockdown | 1 |
| 214 | subepimyocardium | 1 |
| 215 | symptoms/deteriorations | 1 |
| 216 | tibia-first | 1 |
| 217 | time-averaging | 1 |
| 218 | times-to-ponv | 1 |
| 219 | transanal/perineal | 1 |
| 220 | trpv1+/peptidergic | 1 |
| 221 | tyr-vx001 | 1 |
| 222 | ultra-micro-levels | 1 |
| 223 | underpresence | 1 |
| 224 | underprosecution | 1 |
| 225 | urethrocystoscopic | 1 |
| 226 | ve-deficient | 1 |
| 227 | wgt | 1 |
| 228 | znpic/kg | 1 |
| 229 | ~1/5 | 1 |
| 1 | 'characteristics | 2 |
| 2 | 'proportion | 5 |
| 3 | 'region | 1 |
| 4 | 'toxemia | 1 |
| 5 | 0-6-month | 1 |
| 6 | 0.1mg/g | 1 |
| 7 | 0.450mg | 1 |
| 8 | 16g/day | 1 |
| 9 | 2,6-dideoxyhexoses | 1 |
| 10 | 23-o-methylation | 1 |
| 11 | 3'-amp-induced | 1 |
| 12 | 3-alkenylation | 3 |
| 13 | 3-alkylation | 3 |
| 14 | 3-o-acetylation | 1 |
| 15 | 3.2g | 1 |
| 16 | 4'-position | 7 |
| 17 | 5-methoxy-moieties | 1 |
| 18 | 54mg | 1 |
| 19 | 5drop/kg | 1 |
| 20 | 8,9-positions | 1 |
| 21 | =2/5 | 1 |
| 22 | abolishment | 15 |
| 23 | absence | 9,285 |
| 24 | absence/presence | 11 |
| 25 | acute-exacerbations | 1 |
| 26 | adaptiveness | 8 |
| 27 | adolescent-report | 1 |
| 28 | advisability | 20 |
| 29 | aleviations | 1 |
| 30 | anatomical/physiological | 1 |
| 31 | andinjustice | 1 |
| 32 | antennal- | 1 |
| 33 | anti-conservatism | 1 |
| 34 | arg-vx001 | 2 |
| 35 | arm-forearm | 2 |
| 36 | avirulence | 2 |
| 37 | axilla-surgery | 1 |
| 38 | banishment | 1 |
| 39 | beef-consumption | 2 |
| 40 | bprs-score | 1 |
| 41 | brief-symptom-inventory-18 | 1 |
| 42 | broadbeam | 1 |
| 43 | bypass/resection | 1 |
| 44 | c1-carboxyl | 1 |
| 45 | ca2+-permeability | 1 |
| 46 | cattaneo-vernotte | 1 |
| 47 | cav- | 2 |
| 48 | cdc28 | 1 |
| 49 | cdh1-347g/ga | 1 |
| 50 | cis-regulation | 2 |
| 51 | clarithromycin-amoxicillin | 1 |
| 52 | classical- | 1 |
| 53 | clinical-course | 1 |
| 54 | co-inhibitors | 1 |
| 55 | cocirculation | 5 |
| 56 | conclusiveness | 15 |
| 57 | conut® | 1 |
| 58 | county- | 1 |
| 59 | cu-se | 1 |
| 60 | culture-negatives | 1 |
| 61 | curer | 2 |
| 62 | curve-ness | 2 |
| 63 | cytodestruction | 1 |
| 64 | dam-to-placenta | 1 |
| 65 | decompression/release | 1 |
| 66 | deimplementation | 1 |
| 67 | dendrimerization | 1 |
| 68 | di-sulfate | 1 |
| 69 | didactic-only | 1 |
| 70 | disbeliefs | 1 |
| 71 | disease-spectrum | 1 |
| 72 | disproof | 1 |
| 73 | disunity | 2 |
| 74 | dose/type | 2 |
| 75 | dw-r. | 1 |
| 76 | earliness | 4 |
| 77 | eclabion | 1 |
| 78 | ecws | 2 |
| 79 | efficicacy | 2 |
| 80 | endodrainage | 1 |
| 81 | enormity | 7 |
| 82 | entranceability | 1 |
| 83 | eortc-qlqc30 | 1 |
| 84 | erk- | 1 |
| 85 | ethylacetate-fraction | 2 |
| 86 | eurotiales | 1 |
| 87 | existence | 1,512 |
| 88 | explicitness | 3 |
| 89 | extrudability | 2 |
| 90 | f-60 | 1 |
| 91 | face/forehead | 1 |
| 92 | fracture/operation | 3 |
| 93 | freguency | 2 |
| 94 | full-texts | 3 |
| 95 | gastrin- | 1 |
| 96 | globality | 1 |
| 97 | greying | 2 |
| 98 | gut-hepatic | 1 |
| 99 | hemorrhea | 1 |
| 100 | ho/co | 1 |
| 101 | hydrophosphination | 2 |
| 102 | hypermethylations | 1 |
| 103 | hypopnoea/hour | 1 |
| 104 | imperfectness | 2 |
| 105 | inhibition/depletion | 2 |
| 106 | initial-pat | 1 |
| 107 | instalment | 2 |
| 108 | intermediating | 1 |
| 109 | ionicity | 3 |
| 110 | jeju-do | 1 |
| 111 | keratitis/keratopathy | 1 |
| 112 | ldlr-cc | 1 |
| 113 | levels/patterns | 1 |
| 114 | liberal- | 1 |
| 115 | liquidform | 1 |
| 116 | load-dependence | 2 |
| 117 | lodogen | 1 |
| 118 | m-methoxyphenyl | 1 |
| 119 | maxillary- | 1 |
| 120 | menbunong | 1 |
| 121 | mensapo | 1 |
| 122 | metaregister | 255 |
| 123 | mid-wbc | 1 |
| 124 | midazolam-group | 1 |
| 125 | midvault | 1 |
| 126 | minutia | 1 |
| 127 | mono-beta-xyloside | 1 |
| 128 | mono-ubiquitylation | 1 |
| 129 | msus- | 1 |
| 130 | multifunctionality | 3 |
| 131 | myth-reality | 1 |
| 132 | n109 | 1 |
| 133 | naguales | 1 |
| 134 | near-clearing | 1 |
| 135 | nerve-nerve | 1 |
| 136 | newness | 4 |
| 137 | next-of-kin | 2 |
| 138 | nhe6 | 1 |
| 139 | nickel-producing | 1 |
| 140 | non-adenomatous | 2 |
| 141 | non-collection | 1 |
| 142 | non-consumption | 1 |
| 143 | non-eruption | 2 |
| 144 | non-occurrence | 6 |
| 145 | non-presence | 2 |
| 146 | nonactivation | 1 |
| 147 | nonexistence | 3 |
| 148 | nonpractice | 1 |
| 149 | nonreceipt | 5 |
| 150 | nonrespect | 1 |
| 151 | o-iodoanilides | 1 |
| 152 | ocurrence | 2 |
| 153 | off-warfarin | 1 |
| 154 | orchestration | 10 |
| 155 | over-expressions | 4 |
| 156 | over-ordination | 1 |
| 157 | over-recording | 1 |
| 158 | overgrading | 1 |
| 159 | overthinning | 1 |
| 160 | patho-physiology | 5 |
| 161 | pathoetiology | 5 |
| 162 | permissibility | 2 |
| 163 | perpetuation | 47 |
| 164 | persistence/calcification | 1 |
| 165 | pervasion | 2 |
| 166 | pervasiveness | 19 |
| 167 | petichiae | 1 |
| 168 | photophysics | 10 |
| 169 | post-clamping | 1 |
| 170 | pou5f1- | 1 |
| 171 | preemption | 1 |
| 172 | presence | 22,771 |
| 173 | presence/absence | 109 |
| 174 | presences | 5 |
| 175 | principality | 6 |
| 176 | psc833- | 1 |
| 177 | pseudo-delayedness | 1 |
| 178 | purveyor | 1 |
| 179 | quick-disabilities | 2 |
| 180 | raloxifene- | 1 |
| 181 | re-appearance | 3 |
| 182 | reconsolidate | 1 |
| 183 | regimentation | 3 |
| 184 | reinstallation | 2 |
| 185 | relationship-causation | 1 |
| 186 | remifentinal | 1 |
| 187 | restaging/follow-up | 1 |
| 188 | retro-claisen/retro-hetero-diels-alder | 1 |
| 189 | revitalisation | 2 |
| 190 | rhizomorphs | 1 |
| 191 | ring-cladding | 1 |
| 192 | ringer's-pretreated | 1 |
| 193 | rls-quality | 2 |
| 194 | rv-5h-egfp | 4 |
| 195 | s-oxygenations | 1 |
| 196 | score/duration | 2 |
| 197 | selective-invasive | 1 |
| 198 | selenoamides | 1 |
| 199 | selenomethionine/kg | 1 |
| 200 | shade-drying | 2 |
| 201 | sham-tms | 1 |
| 202 | single-cpg | 1 |
| 203 | sirna-knockdown | 1 |
| 204 | subepimyocardium | 1 |
| 205 | sugammadex-rocuronium | 3 |
| 206 | sultanate | 7 |
| 207 | supremacy | 10 |
| 208 | symptoms/deteriorations | 1 |
| 209 | theorisation | 2 |
| 210 | thrombovasculitis | 2 |
| 211 | tibia-first | 1 |
| 212 | time-averaging | 1 |
| 213 | timecourse | 2 |
| 214 | times-to-ponv | 1 |
| 215 | transactivity | 4 |
| 216 | transanal/perineal | 1 |
| 217 | trpv1+/peptidergic | 1 |
| 218 | type-conformity | 2 |
| 219 | tyr-vx001 | 1 |
| 220 | ultra-micro-levels | 1 |
| 221 | underpresence | 1 |
| 222 | underprosecution | 1 |
| 223 | underweighting | 2 |
| 224 | up-take | 3 |
| 225 | urethrocystoscopic | 1 |
| 226 | ve-deficient | 1 |
| 227 | wgt | 1 |
| 228 | znpic/kg | 1 |
| 229 | ~1/5 | 1 |
| 1 | pou5f1- | 1 |
| 2 | psc833- | 1 |
| 3 | raloxifene- | 1 |
| 4 | erk- | 1 |
| 5 | classical- | 1 |
| 6 | antennal- | 1 |
| 7 | liberal- | 1 |
| 8 | gastrin- | 1 |
| 9 | msus- | 1 |
| 10 | cav- | 2 |
| 11 | maxillary- | 1 |
| 12 | county- | 1 |
| 13 | dw-r. | 1 |
| 14 | eortc-qlqc30 | 1 |
| 15 | f-60 | 1 |
| 16 | arg-vx001 | 2 |
| 17 | tyr-vx001 | 1 |
| 18 | ~1/5 | 1 |
| 19 | =2/5 | 1 |
| 20 | nhe6 | 1 |
| 21 | brief-symptom-inventory-18 | 1 |
| 22 | cdc28 | 1 |
| 23 | n109 | 1 |
| 24 | hemorrhea | 1 |
| 25 | cdh1-347g/ga | 1 |
| 26 | 'toxemia | 1 |
| 27 | minutia | 1 |
| 28 | dam-to-placenta | 1 |
| 29 | mid-wbc | 1 |
| 30 | ldlr-cc | 1 |
| 31 | trpv1+/peptidergic | 1 |
| 32 | urethrocystoscopic | 1 |
| 33 | gut-hepatic | 1 |
| 34 | face/forehead | 1 |
| 35 | 3'-amp-induced | 1 |
| 36 | ringer's-pretreated | 1 |
| 37 | petichiae | 1 |
| 38 | nonpractice | 1 |
| 39 | andinjustice | 1 |
| 40 | re-appearance | 3 |
| 41 | load-dependence | 2 |
| 42 | avirulence | 2 |
| 43 | non-occurrence | 6 |
| 44 | ocurrence | 2 |
| 45 | absence | 9,285 |
| 46 | presence/absence | 109 |
| 47 | presence | 22,771 |
| 48 | non-presence | 2 |
| 49 | absence/presence | 11 |
| 50 | underpresence | 1 |
| 51 | existence | 1,512 |
| 52 | nonexistence | 3 |
| 53 | mono-beta-xyloside | 1 |
| 54 | endodrainage | 1 |
| 55 | up-take | 3 |
| 56 | dose/type | 2 |
| 57 | bprs-score | 1 |
| 58 | cu-se | 1 |
| 59 | decompression/release | 1 |
| 60 | clinical-course | 1 |
| 61 | timecourse | 2 |
| 62 | reconsolidate | 1 |
| 63 | di-sulfate | 1 |
| 64 | sultanate | 7 |
| 65 | cattaneo-vernotte | 1 |
| 66 | selective-invasive | 1 |
| 67 | nerve-nerve | 1 |
| 68 | disproof | 1 |
| 69 | 0.1mg/g | 1 |
| 70 | 3.2g | 1 |
| 71 | znpic/kg | 1 |
| 72 | selenomethionine/kg | 1 |
| 73 | 5drop/kg | 1 |
| 74 | 0.450mg | 1 |
| 75 | 54mg | 1 |
| 76 | nickel-producing | 1 |
| 77 | overgrading | 1 |
| 78 | ring-cladding | 1 |
| 79 | over-recording | 1 |
| 80 | time-averaging | 1 |
| 81 | overthinning | 1 |
| 82 | post-clamping | 1 |
| 83 | near-clearing | 1 |
| 84 | intermediating | 1 |
| 85 | underweighting | 2 |
| 86 | greying | 2 |
| 87 | shade-drying | 2 |
| 88 | menbunong | 1 |
| 89 | single-cpg | 1 |
| 90 | 0-6-month | 1 |
| 91 | anatomical/physiological | 1 |
| 92 | transanal/perineal | 1 |
| 93 | remifentinal | 1 |
| 94 | m-methoxyphenyl | 1 |
| 95 | c1-carboxyl | 1 |
| 96 | broadbeam | 1 |
| 97 | arm-forearm | 2 |
| 98 | liquidform | 1 |
| 99 | anti-conservatism | 1 |
| 100 | subepimyocardium | 1 |
| 101 | sugammadex-rocuronium | 3 |
| 102 | disease-spectrum | 1 |
| 103 | lodogen | 1 |
| 104 | next-of-kin | 2 |
| 105 | clarithromycin-amoxicillin | 1 |
| 106 | off-warfarin | 1 |
| 107 | eclabion | 1 |
| 108 | 'region | 1 |
| 109 | pervasion | 2 |
| 110 | persistence/calcification | 1 |
| 111 | reinstallation | 2 |
| 112 | cocirculation | 5 |
| 113 | cis-regulation | 2 |
| 114 | 23-o-methylation | 1 |
| 115 | 3-alkylation | 3 |
| 116 | 3-alkenylation | 3 |
| 117 | 3-o-acetylation | 1 |
| 118 | mono-ubiquitylation | 1 |
| 119 | over-ordination | 1 |
| 120 | hydrophosphination | 2 |
| 121 | fracture/operation | 3 |
| 122 | orchestration | 10 |
| 123 | score/duration | 2 |
| 124 | revitalisation | 2 |
| 125 | theorisation | 2 |
| 126 | relationship-causation | 1 |
| 127 | deimplementation | 1 |
| 128 | regimentation | 3 |
| 129 | perpetuation | 47 |
| 130 | nonactivation | 1 |
| 131 | dendrimerization | 1 |
| 132 | ethylacetate-fraction | 2 |
| 133 | non-collection | 1 |
| 134 | bypass/resection | 1 |
| 135 | cytodestruction | 1 |
| 136 | inhibition/depletion | 2 |
| 137 | 4'-position | 7 |
| 138 | preemption | 1 |
| 139 | beef-consumption | 2 |
| 140 | non-consumption | 1 |
| 141 | non-eruption | 2 |
| 142 | 'proportion | 5 |
| 143 | underprosecution | 1 |
| 144 | sirna-knockdown | 1 |
| 145 | ho/co | 1 |
| 146 | jeju-do | 1 |
| 147 | mensapo | 1 |
| 148 | rv-5h-egfp | 4 |
| 149 | restaging/follow-up | 1 |
| 150 | midazolam-group | 1 |
| 151 | retro-claisen/retro-hetero-diels-alder | 1 |
| 152 | curer | 2 |
| 153 | metaregister | 255 |
| 154 | purveyor | 1 |
| 155 | hypopnoea/hour | 1 |
| 156 | photophysics | 10 |
| 157 | 'characteristics | 2 |
| 158 | presences | 5 |
| 159 | o-iodoanilides | 1 |
| 160 | selenoamides | 1 |
| 161 | 5-methoxy-moieties | 1 |
| 162 | quick-disabilities | 2 |
| 163 | eurotiales | 1 |
| 164 | naguales | 1 |
| 165 | 2,6-dideoxyhexoses | 1 |
| 166 | culture-negatives | 1 |
| 167 | disbeliefs | 1 |
| 168 | rhizomorphs | 1 |
| 169 | thrombovasculitis | 2 |
| 170 | ultra-micro-levels | 1 |
| 171 | sham-tms | 1 |
| 172 | over-expressions | 4 |
| 173 | acute-exacerbations | 1 |
| 174 | aleviations | 1 |
| 175 | hypermethylations | 1 |
| 176 | s-oxygenations | 1 |
| 177 | symptoms/deteriorations | 1 |
| 178 | 8,9-positions | 1 |
| 179 | levels/patterns | 1 |
| 180 | co-inhibitors | 1 |
| 181 | curve-ness | 2 |
| 182 | pseudo-delayedness | 1 |
| 183 | pervasiveness | 19 |
| 184 | conclusiveness | 15 |
| 185 | adaptiveness | 8 |
| 186 | earliness | 4 |
| 187 | imperfectness | 2 |
| 188 | explicitness | 3 |
| 189 | newness | 4 |
| 190 | full-texts | 3 |
| 191 | non-adenomatous | 2 |
| 192 | ecws | 2 |
| 193 | initial-pat | 1 |
| 194 | nonrespect | 1 |
| 195 | wgt | 1 |
| 196 | midvault | 1 |
| 197 | ve-deficient | 1 |
| 198 | abolishment | 15 |
| 199 | banishment | 1 |
| 200 | instalment | 2 |
| 201 | nonreceipt | 5 |
| 202 | adolescent-report | 1 |
| 203 | tibia-first | 1 |
| 204 | times-to-ponv | 1 |
| 205 | 16g/day | 1 |
| 206 | efficicacy | 2 |
| 207 | supremacy | 10 |
| 208 | freguency | 2 |
| 209 | patho-physiology | 5 |
| 210 | pathoetiology | 5 |
| 211 | keratitis/keratopathy | 1 |
| 212 | didactic-only | 1 |
| 213 | axilla-surgery | 1 |
| 214 | ionicity | 3 |
| 215 | globality | 1 |
| 216 | myth-reality | 1 |
| 217 | multifunctionality | 3 |
| 218 | principality | 6 |
| 219 | rls-quality | 2 |
| 220 | extrudability | 2 |
| 221 | entranceability | 1 |
| 222 | ca2+-permeability | 1 |
| 223 | advisability | 20 |
| 224 | permissibility | 2 |
| 225 | type-conformity | 2 |
| 226 | enormity | 7 |
| 227 | disunity | 2 |
| 228 | transactivity | 4 |
| 229 | conut® | 1 |